Medical Director and Professor of Medicine Barrow Neurological Institute Phoenix, Arizona, United States
Disclosure(s):
Kevin C.J Yuen, MD, FRCP (UK), FACE: Ascendis Pharma: Advisory Board (), Contracted Research (Principal Investigators must provide information, even if received by the institution) (); Camurus: Advisory Board (); Chiesi: Advisory Board (); Crinetics: Advisory Board (); Neurocrine: Advisory Board (), Speakers' Bureau (); Novo Nordisk: Advisory Board (), Contracted Research (Principal Investigators must provide information, even if received by the institution) (), Speakers' Bureau (); recordati: Advisory Board (), Speakers' Bureau (); Sparrow Therapeutics: Contracted Research (Principal Investigators must provide information, even if received by the institution) ()
Learning Objectives:
Discuss knowledge gaps and obstacles of transitioning adolescents with pituitary tumors to adult endocrine care services.
Describe the dynamic changes of pituitary hormones during the transition years and how endocrinopathies can be managed during and after transition to adult endocrine care.
Describe the possible outcomes after transition and develop management strategies in childhood and adolescence to optimize physiological outcomes in adulthood.
Acknowledge the importance of a multidisciplinary team approach in optimizing the management of pituitary tumors and their clinical sequelae after transition into adulthood.
.jpg)
.jpg)
